Skip to main content
Shanghai ZJ Bio-Tech Co., Ltd logo

Shanghai ZJ Bio-Tech Co., Ltd — Investor Relations & Filings

Ticker · 688317 ISIN · CNE100005DB6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 545 across all filing types
Latest filing 2026-06-02 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688317

About Shanghai ZJ Bio-Tech Co., Ltd

https://m.liferiver.com.cn/

Shanghai ZJ Bio-Tech Co., Ltd., operating under the brand Liferiver, specializes in the development, manufacture, and distribution of molecular diagnostic reagents and equipment. The company’s core expertise lies in real-time PCR technology, providing a comprehensive portfolio of over 400 diagnostic kits. These solutions target a broad spectrum of infectious diseases, including viral hepatitis, respiratory infections, sexually transmitted diseases, and zoonotic pathogens. Beyond clinical diagnostics, the company offers specialized kits for food safety testing and veterinary health monitoring. Its products are utilized by clinical laboratories, hospitals, and public health institutions worldwide. Many diagnostic assays have achieved international recognition through CE marking and World Health Organization (WHO) listings. The company focuses on delivering high-sensitivity, high-specificity molecular tools to facilitate rapid pathogen detection and disease management.

Recent filings

Filing Released Lang Actions
之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 92% confidence The document is a formal announcement by Shanghai Zhijiang Bio-Tech regarding the progress of its 2025 third share repurchase program conducted via centralized bidding. It provides month-end cumulative share repurchase numbers, prices, and amounts, fitting the definition of a Transaction in Own Shares (buyback). It is not a broader financial report, proxy statement, or dividend notice. Therefore, it is classified as POS.
2026-06-02 Chinese
之江生物：关于自愿披露公司产品获得相关认证的公告
Regulatory Filings Classification · 85% confidence The document is a voluntary corporate announcement disclosing product certifications obtained by the company and its subsidiary. It does not contain financial statements, officer certifications, voting results, dividends, share transactions, or other specific filing types. It is a general regulatory announcement, fitting the fallback category for miscellaneous filings.
2026-05-19 Chinese
之江生物：关于注销公司部分回购股份并减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 92% confidence The document is an official announcement by Shanghai Zhijiang Biotech regarding the cancellation of repurchased shares and a reduction in registered capital. It details the change in share capital, the number of shares cancelled, and creditor notification procedures under the Company Law. This is not a repurchase notice but a capital change notice, fitting the Share Issue/Capital Change category (SHA).
2026-05-14 Chinese
之江生物：2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official announcement of the resolutions and voting results from the 2025 Annual General Meeting of shareholders (AGM), detailing attendance, each proposal, vote counts, and outcomes. This aligns with the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-14 Chinese
之江生物：关于召开2025年年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2025 annual performance explanation meeting (业绩说明会) by Shanghai Zhijiang Bio-Technology Co., Ltd. It provides details about the meeting time, location, participants, and how investors can participate and ask questions. The document references that the 2025 annual report has already been published on April 24, 2026, and this meeting is to explain and discuss the annual results. The document itself does not contain the annual report or detailed financial data but is an announcement of an investor presentation event related to the annual results. Given the nature of the document as a notice for an investor meeting focused on financial results explanation, it fits best under Investor Presentation (IP). The document length is short (1353 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is Investor Presentation (IP) with high confidence.
2026-05-07 Chinese
之江生物：关于2025年第三次以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by Shanghai Zhijiang Bio-Technology Co., Ltd. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but focuses on the company's own shares repurchase activity. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on share buybacks or sales by the company itself.
2026-05-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.